| Outcomes for COPD pharmacological trials: from lung function to biomarkers M Cazzola, W MacNee, FJ Martinez, KF Rabe, LG Franciosi, PJ Barnes, ... European respiratory journal 31 (2), 416-469, 2008 | 1079 | 2008 |
| Symptom variability in patients with severe COPD: a pan-European cross-sectional study R Kessler, MR Partridge, M Miravitlles, M Cazzola, C Vogelmeier, ... European Respiratory Journal 37 (2), 264-272, 2011 | 581 | 2011 |
| Pharmacology and therapeutics of bronchodilators M Cazzola, CP Page, L Calzetta, MG Matera Pharmacological Reviews 64 (3), 450-504, 2012 | 531 | 2012 |
| ACE2: the major cell entry receptor for SARS-CoV-2 F Scialo, A Daniele, F Amato, L Pastore, MG Matera, M Cazzola, ... Lung 198, 867-877, 2020 | 425 | 2020 |
| The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD M Cazzola, M Molimard Pulmonary pharmacology & therapeutics 23 (4), 257-267, 2010 | 367 | 2010 |
| Outdoor air pollution, climatic changes and allergic bronchial asthma G D'Amato, G Liccardi, M D'amato, M Cazzola European Respiratory Journal 20 (3), 763-776, 2002 | 358 | 2002 |
| β2-Agonist Therapy in Lung Disease M Cazzola, CP Page, P Rogliani, MG Matera American journal of respiratory and critical care medicine 187 (7), 690-696, 2013 | 318 | 2013 |
| A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD L Calzetta, P Rogliani, MG Matera, M Cazzola Chest 149 (5), 1181-1196, 2016 | 269 | 2016 |
| Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia M Cazzola, F Imperatore, A Salzillo, F Di Perna, F Calderaro, ... Chest 114 (2), 411-415, 1998 | 267 | 1998 |
| Night-time symptoms: a forgotten dimension of COPD A Agusti, J Hedner, JM Marin, F Barbé, M Cazzola, S Rennard European Respiratory Review 20 (121), 183-194, 2011 | 265 | 2011 |
| Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis M Cazzola, L Calzetta, C Page, J Jardim, AG Chuchalin, P Rogliani, ... European Respiratory Review 24 (137), 451-461, 2015 | 253 | 2015 |
| The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy G D'amato, G Liccardi, M D'amato, M Cazzola Respiratory medicine 95 (7), 606-611, 2001 | 253 | 2001 |
| Prevalence of comorbidities in patients with chronic obstructive pulmonary disease M Cazzola, G Bettoncelli, E Sessa, C Cricelli, G Biscione Respiration 80 (2), 112-119, 2010 | 252 | 2010 |
| Markers of disease severity in chronic obstructive pulmonary disease LG Franciosi, CP Page, BR Celli, M Cazzola, MJ Walker, M Danhof, ... Pulmonary pharmacology & therapeutics 19 (3), 189-199, 2006 | 250 | 2006 |
| Integrated care pathways for airway diseases (AIRWAYS-ICPs) J Bousquet, A Addis, I Adcock, I Agache, A Agusti, A Alonso, ... European Respiratory Journal 44 (2), 304-323, 2014 | 215 | 2014 |
| Optimizing drug delivery in COPD: the role of inhaler devices P Rogliani, L Calzetta, A Coppola, F Cavalli, J Ora, E Puxeddu, ... Respiratory medicine 124, 6-14, 2017 | 210 | 2017 |
| Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study M Cazzola, MG Matera, G Santangelo, A Vinciguerra, F Rossi, G D'amato Respiratory medicine 89 (5), 357-362, 1995 | 209 | 1995 |
| The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections F Blasi, C Page, GM Rossolini, L Pallecchi, MG Matera, P Rogliani, ... Respiratory medicine 117, 190-197, 2016 | 205 | 2016 |
| β2‐adrenoceptor agonists: current and future direction M Cazzola, L Calzetta, MG Matera British journal of pharmacology 163 (1), 4-17, 2011 | 204 | 2011 |
| Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? F Perrotta, MG Matera, M Cazzola, A Bianco Respiratory medicine 168, 105996, 2020 | 194 | 2020 |
Maria Gabriella MateraNapoliVerifierad e-postadress på unicampania.it
